Fig. 6: DB-LNP-mediated hepatic delivery of FGF21 mRNA. | Nature Communications

Fig. 6: DB-LNP-mediated hepatic delivery of FGF21 mRNA.

From: In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors

Fig. 6

a LNP-mediated FGF21 mRNA delivery (n = 4 biologically independent samples). Male mice were fed a HFD for three weeks to induce obesity (body weight ~30 g) and fatty liver. These obese mice were i.v. injected with FGF21 mRNA-loaded LNPs at an mRNA dose of 0.25 mg/kg. Serum was collected at the indicated time points for ELISA analysis of FGF21. AUC of FGF21 exposure during the time interval 0–48 h was determined. Statistical significance was evaluated by an unpaired two-tailed Student’s t-test. b A scheme of FGF21 mRNA therapy in HFD-induced obese mice. Obese mice were i.v. injected with various LNP formulations at an mRNA dose of 0.25 mg/kg every other day for three doses. Male mice fed a normal chow diet (NCD) were used as a control group. c Body weight growth curve (n = 4 biologically independent samples). d Body weight on Day 6 (n = 4 biologically independent samples). Statistical significance was evaluated by a one-way ANOVA with Tukey’s correction. e Liver weight (n = 4 biologically independent samples). Statistical significance was evaluated by a one-way ANOVA with Tukey’s correction. f Representative images of liver histological examinations (H&E staining). Scale bars: 100 μm. g Liver steatosis score (n = 12). A total of 12 images for each group (three random fields for each liver section, four mice per group) were analyzed semi-quantitatively for liver steatosis. Statistical significance was evaluated by a one-way ANOVA with Tukey’s correction. Data are presented as mean ± SD. Source data are provided as a Source Data file.

Back to article page